How Accurate Is a Biopsy for Fat-Poor AML vs Kidney Cancer?

A kidney biopsy can be highly accurate and often provides the information needed to guide your care. However, while biopsies are excellent at detecting kidney cancer in general ^[1], distinguishing a fat-poor angiomyolipoma (AML) from renal cell carcinoma (RCC) presents unique challenges. Because errors, inconclusive results, or false negatives can occur, a biopsy should always be interpreted alongside your imaging scans and clinical history.

Understanding why a biopsy might not give a definitive answer can help you and your doctor make informed decisions about your next steps.

The Challenge of Looking Alike

Standard AMLs are usually easy to diagnose on imaging because they contain visible fat. However, fat-poor AMLs lack this visible fat, making them look very similar to kidney cancer on CT or MRI scans ^[2].

When a biopsy is performed, the challenge continues under the microscope. Fat-poor AMLs and epithelioid AMLs (a specific, less common subtype that can sometimes behave aggressively and requires different management) can have cells and structures that closely mimic kidney cancer ^{[3] [4]}. If a pathologist only looks at the general shape of the cells, the two tumors can be easily confused.

To tell them apart, pathologists rely on immunohistochemistry—laboratory tests that check for specific proteins in the tumor cells:

• Melanocytic markers (like HMB45 or Melan-A) and smooth-muscle markers are typically found in AMLs ^[5].
• Renal and epithelial markers (like PAX8 or cytokeratin) are typically found in kidney cancer ^[5].

While this panel of markers often helps substantially, it is not guaranteed to settle the diagnosis. Staining can be patchy, overlapping, or absent, especially in epithelioid AMLs. Because these tumors are rare and tricky to read, having an expert uropathologist (a pathologist specializing in urinary tract diseases) review the sample is highly recommended ^[6].

Decoding Your Biopsy Result

When your doctor receives the pathology report, the exact wording matters. A report might say:

• Diagnostic of AML: The sample had enough tissue and clear features to confidently identify an AML.
• Favors or Consistent with AML: The features suggest AML, but the sample was limited or the stains were mixed, leaving some uncertainty.
• Negative for Malignancy: No cancer cells were seen, but this does not automatically prove the mass is a benign AML—the needle may have just missed the tumor.
• Nondiagnostic: The sample did not contain enough abnormal tissue to make any determination. This happens in about 10% to 15% of all kidney mass biopsies ^{[7] [8]}.

A nondiagnostic result might happen if the mass is very small, fluid-filled (cystic), or if the needle only captures normal kidney tissue or dead cells ^{[9] [10]}. It is crucial to know that a nondiagnostic biopsy is not a benign (non-cancerous) result. It simply means the doctor did not get the tissue they needed.

The Risk of Sampling Error

Tumors are not always uniform; they can be heterogeneous, meaning they are made up of different types of tissue in different areas.

Sampling error occurs when the biopsy needle hits a benign part of the tumor but misses the cancerous part. If the biopsy comes back “negative” but your doctor is still highly suspicious based on your imaging scans, they may not entirely trust the biopsy result. In one study, when a highly selected group of patients with a “negative” biopsy still went on to have surgery because their doctors remained suspicious, cancer was actually found in over a third of those cases ^[7]. This statistic does not apply to everyone with a negative biopsy, but it highlights why clinical suspicion is so important.

Next Steps: When Results are Uncertain

If your biopsy is nondiagnostic, or if the result doesn’t match what the scans suggest (a “discordant” result), your care team will weigh the risks of various options:

• Expert Pathology Review: Sending the existing biopsy slides to a specialized cancer center for a second opinion can sometimes clarify the diagnosis ^[6].
• Repeat Biopsy: A second biopsy provides a diagnosis in about 80% of initially nondiagnostic cases in some studies, though success depends on the size and location of the mass ^[7].
• Active Surveillance: Closely monitoring the mass with scheduled imaging. This is often used for small masses if the risk of cancer is deemed low, but you should ask what specific changes (like tumor growth) would trigger treatment ^[11].
• Treatment (Surgery or Ablation): If a repeat biopsy isn’t feasible, or if there is high suspicion of cancer or a risky epithelioid AML subtype, your doctor may recommend treating the mass. Options include ablation (destroying the tumor with heat or cold) or partial nephrectomy (surgically removing the tumor while sparing the healthy kidney) ^[12].

All procedures carry risks: biopsies can cause bleeding or pain, while surgery involves a longer recovery, potential urine leakage, and changes in kidney function. Your doctor will help you balance these risks against the uncertainty of the diagnosis. If you experience severe pain, worsening blood in your urine, or a fever after a biopsy, contact your clinical team immediately.